Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05946798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion moved earlier from Jun 30, 2027 to Jun 30, 2026
    • Enrollment closed, study ongoing
    • Site details revised
    v5
  2. Primary completion date: Jun 2026 to Jun 30, 2027
    • Study completion date: Jun 2027 to Jun 1, 2028
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2023 to Aug 30, 2023
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Anna Stanhewicz, PhD
12 trials monitored
See 1 trial at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.
Trial Details
NCT Number NCT05946798
Lead Sponsor Anna Stanhewicz, PhD
Conditions
(from sponsor)		 Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Related terms Diabetes, Gestational
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov